Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction

Journal of Invasive Cardiology

Volumn 18, Issue 2, 2006, Pages 59-62

  Gruberg, Luis ^a   Suleiman, Mahmoud ^a   Kapeliovich, Michael ^a   Hammerman, Haim ^a   Grenadier, Ehud ^a   Boulus, Monther ^a   Amikam, Shlomo ^a   Markiewicz, Walter ^a   Beyar, Rafael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; EPTIFIBATIDE; STREPTOKINASE; TIROFIBAN;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; CLINICAL TRIAL; HOSPITAL PATIENT; HUMAN; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; REVASCULARIZATION; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COHORT STUDIES; FEMALE; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STENTS; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33645976803     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
2. The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: Phase 1 findings. N Engl J Med 1985;312:932-938.
3. Simes RJ, Topol EJ, Holmes DR, et al. for the GUSTO-1 Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Circulation 1995;91:1923-1928.
4. Ellis SG, da Silva ER, Heindryckx G, et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation 1994;90:2280-2284.
5. Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197-203.
6. Prendergast BD, Shandall A, Buchalter MB. What do we do when thrombolysis fails? A United Kingdom survey. Int J Cardiol 1997;61:39-42.
7. Miller JM, Smalling R, Ohman EM, et al. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO III Trial). Am J Cardiol 1999;84:779-784.
8. Jong P, Cohen EA, Batchelor W, et al. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction. Am Heart J 2001;141:218-225.
9. Petronio AS, Musumeci G, Limbruno U, et al. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. Am Heart J 2002;143:334-341.
10. Sutton AG, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: The Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol 2004;44:287-296.
11. Pepine CJ, Holmes DR, for the Cardiac Catheterization Committee. ACC Expert Consensus Group. Coronary artery stents. J Am Coll Cardiol 1996;28:782-794.
12. Sundlof DW, Rerkpattanapitat P, Wongpraparut N, et al. Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty. Am J Cardiol 1999;83:1569-1571, A7.